Clinical trial supply is the process of providing every material needed to run a clinical trial, from the experimental drug itself to the packaging it ships in, the syringes used to administer it, and the technology that tracks it all. It covers manufacturing, labeling, storage, distribution, inventory management, and eventual destruction of unused products. For pharmaceutical companies and research organizations, getting this right is one of the most operationally complex parts of bringing a new treatment to market.
What Clinical Trial Supply Includes
The term covers two broad categories. The first is the investigational medicinal product (IMP), which is the drug or therapy being tested. This also includes any comparator, meaning an existing approved drug or placebo that some participants receive so researchers can measure the experimental treatment against something. The second category is everything else: the ancillary supplies and equipment that trial sites need to actually conduct the study.
Ancillary supplies span a surprisingly wide range. Lab equipment like centrifuges, pipettes, and glucometers. Treatment devices such as infusion pumps and nebulizers. Diagnostic tools like pulse oximeters and thermometers. And consumables: syringes, sharps containers, fecal collection kits, and more. A single trial might require dozens of different supply lines, each with its own sourcing, shipping, and tracking requirements.
Packaging and Labeling for Blinded Trials
Many clinical trials are “blinded,” meaning participants (and often the doctors treating them) don’t know who is receiving the real drug and who is getting a placebo. The supply chain has to protect that blinding at every step. Drug kits are packaged and labeled so that the active treatment and placebo look identical in size, weight, color, and labeling. Randomness is built into how kits are packaged, shipped to sites, and assigned to individual participants, all to prevent anyone from guessing which treatment a patient received.
Regulatory agencies require specific information on clinical trial labels that differs from what you see on a commercial pharmacy product. Labels must identify the product as investigational, include the trial protocol number, storage conditions, expiration dates, and sponsor contact information. These requirements vary by country, so a multinational trial may need dozens of label versions produced in different languages.
Cold Chain and Temperature Control
Many investigational products, especially biologics and vaccines, must stay within a narrow temperature window from the moment they leave the manufacturer until a patient receives them. This is called the cold chain. For products requiring refrigeration, that window is typically 0 to 8 degrees Celsius.
Maintaining those conditions during transit relies on insulated shipping containers with frozen gel packs, a passive cooling system that’s straightforward but requires careful validation. Research on UK-based clinical trial shipments found that a configuration of three frozen gel packs with a four-hour pre-chill of the container held temperatures within the required range for up to 48 hours during cooler months. Summer shipping required an extra gel pack. Temperature inside the container was monitored at 30-minute intervals to verify compliance. For global trials shipping to tropical climates or remote locations, the logistics become significantly more demanding, often requiring active refrigeration units or specialized couriers.
How Inventory Is Tracked and Managed
Clinical trials use a technology platform called Interactive Response Technology (IRT) to manage the supply chain in real time. IRT automates patient enrollment, randomization (deciding which treatment arm each participant joins), treatment allocation, and inventory tracking across every trial site and storage depot worldwide.
The system’s supply chain capabilities go well beyond simple counting. IRT uses intelligent forecasting to predict future supply needs based on enrollment patterns, so if a trial is recruiting faster than expected in one region, additional shipments can be planned before a shortage develops. Automated resupply triggers shipments before a site runs out of stock. The system tracks lot numbers and expiration dates, preventing sites from dispensing expired products. It manages the full lifecycle from manufacturing through patient dispensing, giving sponsors real-time visibility into where every unit of drug sits at any moment.
Before IRT existed, much of this was handled through phone calls and spreadsheets. The shift to automated systems has reduced errors in treatment assignment and cut the risk of sites running out of drug mid-trial, both problems that can compromise data integrity or force costly delays.
Drug Wastage and Cost
Waste is an unavoidable part of clinical trial supply. Patients drop out, doses get modified, products expire on the shelf, and trials end with unused stock at sites around the world. A study published in JAMA Oncology looking at oral cancer drugs found that the median cost of wastage from dose changes and treatment discontinuation was $1,750 per patient, though in some cases it reached as high as $27,200. On average, wastage accounted for about 1.8% of total treatment cost per patient.
Those numbers may sound modest as percentages, but across a large multinational trial with thousands of participants, they add up quickly. For expensive biologics that cost tens of thousands of dollars per course of treatment, even small improvements in supply forecasting can save millions. This is one reason sponsors invest heavily in IRT and demand forecasting tools.
Reconciliation and Destruction
Every unit of investigational product must be accounted for, from shipment to final disposition. This process, called drug reconciliation, requires trial sites to log exactly how many units they received, how many were dispensed to patients, how many remain unused, and what happened to each one. Reconciliation logs track lot numbers, patient identifiers, quantities, and dates.
Unused or expired products cannot simply be thrown away. They must be returned to the sponsor or sent for certified destruction, typically through a hospital pharmacy or licensed waste facility. A designated person at each site signs off that all drug has been accounted for and either returned or destroyed according to protocol requirements. This documentation is subject to regulatory audit and is a common area of inspection findings when records are incomplete.
Direct-to-Patient Shipping
The traditional model sends investigational products from a central depot to a hospital or clinic, where patients pick them up during scheduled visits. Increasingly, trials are shipping supplies directly to participants’ homes. This approach gained momentum during the COVID-19 pandemic and has continued growing as sponsors try to reduce the burden of travel for participants, particularly those with chronic or serious illnesses.
Direct-to-patient delivery adds logistical complexity. It requires temperature-controlled packaging validated for residential delivery timelines, real-time shipment tracking, and pharmacy oversight to ensure the right patient receives the right drug at the right dose. Regulatory frameworks vary by country. Some jurisdictions allow home delivery of investigational products with pharmacy supervision, while others require the patient to interact with a licensed pharmacist at each dispensing. When done correctly, this model maintains the scientific rigor and compliance standards of a traditional site-based trial while making participation more accessible to people who live far from research centers.
Regulatory Framework
Clinical trial supply operations are governed by Good Manufacturing Practice (GMP) regulations. In the European Union, the specific requirements for investigational products fall under a delegated regulation supplementing the EU Clinical Trials Regulation, along with detailed guidelines in Annex 13 of the EudraLex Volume 4 GMP framework. These rules cover manufacturing, quality control, labeling, storage, shipping, and the responsibilities of the trial sponsor at every stage.
In the United States, the FDA’s current Good Manufacturing Practice regulations apply, with additional guidance specific to investigational drugs. Other major regulatory markets, including Japan, Canada, and Australia, have their own requirements that largely align with international standards but differ in specific details around labeling, import permits, and temperature documentation. For a global trial running across 20 or 30 countries, the supply chain team must navigate all of these frameworks simultaneously, often producing country-specific packaging and documentation for the same product.